Phase 1/2 Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Dec 2021 Results (n=11; as of 13 June 2021) assessing the safety and pharmacokinetics of combination therapy with gilteritinib and atezolizumab for the treatment of relapsed or refractory FLT3-mutated acute myeloid leukemia, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
30 Jun 2021 Status changed from active, no longer recruiting to completed.
10 Jun 2021 Planned End Date changed from 31 Oct 2021 to 30 Jun 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com